P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE
Conflict of interest: No Introduction and Objectives: The impact of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators on the natural history of liver disease is unknown. The objective of this study is to assess changes in the rates of liver transplantation compared to lung t...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124004812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850112271880028160 |
|---|---|
| author | MANUEL MENDIZABAL Claire Cywes Nicolas Muñoz Amay Banker Christian Bermudez Denis Hadjiliadis Peter Abt |
| author_facet | MANUEL MENDIZABAL Claire Cywes Nicolas Muñoz Amay Banker Christian Bermudez Denis Hadjiliadis Peter Abt |
| author_sort | MANUEL MENDIZABAL |
| collection | DOAJ |
| description | Conflict of interest: No Introduction and Objectives: The impact of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators on the natural history of liver disease is unknown. The objective of this study is to assess changes in the rates of liver transplantation compared to lung transplantation since the approval of the new CFTR modulators in October 2019. Patients / Materials and Methods: Patients with CF (PwCF) who were listed for liver or lung transplantation were identified in the OPTN/UNOS database. We compared outcomes between the pre- and post-CFTR modulators eras, 2012-2019 and 2020-2022, respectively. Results and Discussion: Between 2012-2023, 95,254 liver and 28,715 lung transplants were performed, including 138 (0.09%) and 2,129 (7.4%) transplants in PwCF, respectively. The rate of death on the waitlist was not significantly different between eras in either group. For liver transplantation, the median percentage of CF-related listings per year was similar between the two eras 0.13% (0.11-0.17%) in 2012-2019 vs. 0.12% (0.11-0.13%, p=0.18) in 2020-2023. Similarly, the median percentage of CF-related liver transplants per year was 0.14% (0.12-0.20%) vs. 0.14% (0.11-0.16%, p=0.450) (see figure). For lung transplantation waitlist additions per year decreased from 7.58% (6.72-8.17%) to 1.11% (0.95-1.52%) per year from the pre- to the post-modulator era (p<0.001). The median percentage of CF-related transplants per year was 11.18% (10.42-11.94%) in pre-modulator era vs 1.64% (1.56-2.23%) in the post-modulator era (p<0.001). Conclusions: We describe stable liver transplant activity for PwCF in the post-modulator era compared to the pre-modulator era, while the need for lung transplantation declined after the introduction of highly-active CFTR modulators. Long-term data is required to determine the role of CFTR modulators on modifying the need of liver transplantation in PwCF. |
| format | Article |
| id | doaj-art-84a78d5ea2344f2fa4111e35a87fbb70 |
| institution | OA Journals |
| issn | 1665-2681 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj-art-84a78d5ea2344f2fa4111e35a87fbb702025-08-20T02:37:25ZengElsevierAnnals of Hepatology1665-26812024-12-012910169810.1016/j.aohep.2024.101698P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASEMANUEL MENDIZABAL0Claire Cywes1Nicolas Muñoz2Amay Banker3Christian Bermudez4Denis Hadjiliadis5Peter Abt6HOSPITAL UNIVERSITARIO AUSTRAL, Pilar, ArgentinaUniversidad de Pensilvania, Filadelfia, Estados Unidos (EEUU)Universidad de Pensilvania, Filadelfia, Estados Unidos (EEUU)Sir HN Reliance Hospital, Mumbai, IndiaUniversidad de Pensilvania, Filadelfia, Estados Unidos (EEUU)Universidad de Pensilvania, Filadelfia, Estados Unidos (EEUU)Universidad de Pensilvania, Filadelfia, Estados Unidos (EEUU)Conflict of interest: No Introduction and Objectives: The impact of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators on the natural history of liver disease is unknown. The objective of this study is to assess changes in the rates of liver transplantation compared to lung transplantation since the approval of the new CFTR modulators in October 2019. Patients / Materials and Methods: Patients with CF (PwCF) who were listed for liver or lung transplantation were identified in the OPTN/UNOS database. We compared outcomes between the pre- and post-CFTR modulators eras, 2012-2019 and 2020-2022, respectively. Results and Discussion: Between 2012-2023, 95,254 liver and 28,715 lung transplants were performed, including 138 (0.09%) and 2,129 (7.4%) transplants in PwCF, respectively. The rate of death on the waitlist was not significantly different between eras in either group. For liver transplantation, the median percentage of CF-related listings per year was similar between the two eras 0.13% (0.11-0.17%) in 2012-2019 vs. 0.12% (0.11-0.13%, p=0.18) in 2020-2023. Similarly, the median percentage of CF-related liver transplants per year was 0.14% (0.12-0.20%) vs. 0.14% (0.11-0.16%, p=0.450) (see figure). For lung transplantation waitlist additions per year decreased from 7.58% (6.72-8.17%) to 1.11% (0.95-1.52%) per year from the pre- to the post-modulator era (p<0.001). The median percentage of CF-related transplants per year was 11.18% (10.42-11.94%) in pre-modulator era vs 1.64% (1.56-2.23%) in the post-modulator era (p<0.001). Conclusions: We describe stable liver transplant activity for PwCF in the post-modulator era compared to the pre-modulator era, while the need for lung transplantation declined after the introduction of highly-active CFTR modulators. Long-term data is required to determine the role of CFTR modulators on modifying the need of liver transplantation in PwCF.http://www.sciencedirect.com/science/article/pii/S1665268124004812 |
| spellingShingle | MANUEL MENDIZABAL Claire Cywes Nicolas Muñoz Amay Banker Christian Bermudez Denis Hadjiliadis Peter Abt P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE Annals of Hepatology |
| title | P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE |
| title_full | P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE |
| title_fullStr | P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE |
| title_full_unstemmed | P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE |
| title_short | P-84 HAVE CFTR MODULATORS CHANGED THE NEED FOR LIVER TRANSPLANTATION AMONG PATIENTS WITH CYSTIC FIBROSIS? AN ANALYSIS OF THE UNOS DATABASE |
| title_sort | p 84 have cftr modulators changed the need for liver transplantation among patients with cystic fibrosis an analysis of the unos database |
| url | http://www.sciencedirect.com/science/article/pii/S1665268124004812 |
| work_keys_str_mv | AT manuelmendizabal p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT clairecywes p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT nicolasmunoz p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT amaybanker p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT christianbermudez p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT denishadjiliadis p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase AT peterabt p84havecftrmodulatorschangedtheneedforlivertransplantationamongpatientswithcysticfibrosisananalysisoftheunosdatabase |